Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Donor Natural Killer Cell Therapy and Aldesleukin in Treating Patients With High Risk Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
This study is ongoing, but not recruiting participants.
Study NCT00303667 Information provided by Masonic Cancer Center, University of Minnesota
First Received on March 15, 2006. Last Updated on September 27, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myelogenous Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
aldesleukin
natural killer cells
cyclophosphamide
fludarabine phosphate
total body irradiation
Thymoglobulin
Cyclosporin A
Additional drug interventions recognized in this trial
Cyclosporine
Cyclosporins
Fludarabine
Fludarabine monophosphate
Interleukin-2
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Analgesics
Analgesics, Non-Narcotic
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Antiviral Agents
Central Nervous System Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Masonic Cancer Center, University of Minnesota
Back to top of Main Content
